A Phase 3 interventional study of valaciclovir HCl granules in Varicella, sponsored by GlaxoSmithKline. Completed. Open to participants aged 1 Year to 11 Years. Per ClinicalTrials.gov, last updated 2015-04-15.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Chickenpox by GlaxoSmithKline — 6 open to participants now, 6 under way, 6 of them phase 3. Chickenpox · GlaxoSmithKline.
Among the 35 studies in Chickenpox by GlaxoSmithKline, this one is the 27th largest by enrollment of the 29 interventional ones that give a count, is one of 6 that started in 2005, is one of 18 in phase 3, and was the 6th registered.
180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.
Browse Chickenpox studies →6 of the 35 studies in Chickenpox by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 15 mo–6 yrs · Healthy volunteers
GlaxoSmithKline · Sites in Dominican Republic, Honduras
Ages 12 mo–15 mo · Healthy volunteers
GlaxoSmithKline · Sites in United States, Belgium, Estonia and 4 more countries
Ages 12 mo–15 mo · Healthy volunteers
GlaxoSmithKline · Sites in United States, Belgium, Colombia and 8 more countries
Ages 12 mo–15 mo · Healthy volunteers
GlaxoSmithKline · Sites in United States, Bulgaria, Denmark and 5 more countries
Ages 12 mo–15 mo · Healthy volunteers
By country, each count listing its studies:
Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.
This study: 1 Year to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 6 started in 2005.
This study's enrollment of 43 is below the median of 475 across 149 interventional studies indexed under Chickenpox.
Median enrollment 600 across the 29 interventional studies, 379 across the 5 observational. Of the 28 that completed or were terminated, 16 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
3 of the studies in Chickenpox by GlaxoSmithKline that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06693895Phase 3GlaxoSmithKlineA Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age | 2026-11-23 |
| NCT06806137Phase 3GlaxoSmithKlineA Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age | 2026-12-14 |
| NCT06740630Phase 3GlaxoSmithKlineA Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age | 2026-12-25 |
Add all 3 to your calendar (.ics) → With an account.
Among the 35 studies in Chickenpox by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy, and the pharmacokinetics of aciclovir and valaciclovir in children with chickenpox following oral administration of valaciclovir, for the purpose of seeking approval of valaciclovir HCl for the treatment of chickenpox.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Plasma aciclovir concentrations approximately 1 - 2 hours post-dose, and/or 1, 2, 4 and 6 hours following administration of the valaciclovir HCl granules 25mg/kg -dose.
Plasma valaciclovir concentrations approximately 1 - 2 hours post-dose, and/or 1, 2, 4 and 6 hours following administration of the valaciclovir HCl granules 25mg/kg -dose.
No study locations are listed for this record.
The record gives a start of Mar 2005, a primary completion of Aug 2005 and a completion of Aug 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.